MD Anderson Taps IBM Watson to Power "Moon Shots" Miion Aimed at Ending Cancer, Starting with Leukemia

HOUSTON - 18 Oct 2013: The University of Texas MD Anderson Cancer Center and IBM (NYSE:IBM) today announced that MD Anderson is using the IBM Watson cognitive computing system for its mission to eradicate cancer. Following a year-long collaboration, IBM and MD Anderson will showcase a prototype of MD Anderson's Oncology Expert AdvisorTM powered by IBMWatson. The organizations will discuss their shared vision to leverage Watson's cognitive computing power to help patients by enabling clinicians to uncover valuable insights from the cancer center's rich patient and research databases.

MD Anderson's Oncology Expert Advisor powered by IBM Watson is designed to integrate the knowledge of MD Anderson's clinicians and researchers, and to advance the cancer center's goal of treating patients with the most effective, safe and evidence-based standard of care available. Starting with the fight against Leukemia, MD Anderson's Oncology Expert Advisor is expected to help MD Anderson clinicians develop, observe and fine-tune treatment plans for patients, while helping them recognize adverse events that may occur throughout the care continuum. The cognitive-powered technology is also expected to help researchers advance novel discoveries.

MD Anderson's Oncology Expert Advisor is expected to be accessible to the cancer center's network of clinicians through a computer interface or supported mobile devices. This provides clinicians and in turn, patients with immediate, worldwide access to MD Anderson's expertise and resources, and to IBM Watson's technology prowess in quickly extracting crucial insights from large volumes of complex data.

A new era of computing has emerged, in which cognitive systems understand the context within users' questions, uncover answers from Big Data, and improve in performance by continuously learning from experiences. The need for these types of cognitive capabilities in the battle against cancer is clear. The American Cancer Society projects 1.6 million new cancer cases will be diagnosed in the U.S. this year. Within this global epidemic lies a lethal subset: leukemia, which causes nearly one-third of all cancer deaths in children and adolescents younger than 15 years, according to the Leukemia and Lymphoma Society.

Moon Shots and the Big Data Divide

With more than 100,000 patients cared for each year in Houston, and tens of thousands more throughout its regional and national network, MD Anderson has accumulated an unprecedented breadth and depth of clinical oncology data and knowledge. Extracting actionable insights from this information, however, poses a significant challenge. Valuable data from day-to-day patient care and clinical trials is often trapped in the minds and notes of clinicians and researchers, as well as in the remote databases and files of other providers who may have treated these same patients in the past.

Left unaddressed, this divide can cost precious time and resources, and prevent physicians from accessing all the information they might need in order to best treat a patient. It also blocks the pipeline through which clinical research can be completed, evaluated, approved and ultimately used in patient care. Case in point: $95 billion is spent annually on medical research in the United States, yet only six percent of clinical trials are completed on time.

IBM Watson represents a new era of computing, in which data no longer needs to be a challenge, but rather, a catalyst to more efficiently deploy new advances into patient care, says Manoj Saxena, General Manager, IBM Watson Solutions. "By helping researchers and physicians understand the meaning behind each others data, we can empower researchers with evidence to advance novel discoveries, while helping enable physicians to make the best treatment choices or place patients in the right clinical trials."

Preparing Watson for Moon Shots

IBM's Watson technology is expected to play a key role within APOLLO, a technology driven adaptive learning environment that MD Anderson is developing as part of its Moon Shots program. APOLLO enables iterative and continued learning between clinical care and research by creating an environment that streamlines and standardizes the longitudinal collection, ingestion and integration of patient's medical and clinical history, laboratory data as well as research data into MD Anderson's centralized patient data warehouse. Once aggregated, this complex data is linked and made available for deep analyses by advanced analytics to extract novel insights that can lead to improved effectiveness of care and better patient outcomes.

One of the richest sources of valuable clinical insight trapped within this patient data is the unstructured medical and research notes, and test results, for each cancer patient Watson's cognitive capability has been shown to be powerful tool to extract valuable insight from such complex data and MD Andersons Oncology Expert Advisor capability can generate a more comprehensive profile of each cancer patient. This will help physicians better understand the patient's data in the evaluation of a patient's condition.

By identifying and weighing data-driven connections between the attributes in a patient's profile and the knowledge corpus of published medical literature, guidelines in Watson, MD Anderson's Oncology Expert Advisor can provide evidence-based treatment and management options that are personalized to that patient, to aid the physician's treatment and care decisions. These options can include not only standard approved therapies, but also appropriate investigational protocols.

One unique aspect of the MD Anderson Oncology Expert Advisor is that it will not solely rely on established cancer care pathways to recommend appropriate treatment o

LINK:	http://www-03.ibm.com/press/uk/en/pressrelease/42252.wss...
	See more stories from ibm

Most recent headlines